Business Description
Chemomab Therapeutics Ltd
NAICS : 541714
SIC : 8731
ISIN : US16385C1045
Share Class Description:
CMMB: ADRDescription
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 56.66 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -58.7 | |||||
| 3-Year EPS without NRI Growth Rate | -56.2 | |||||
| 3-Year FCF Growth Rate | -61.2 | |||||
| 3-Year Book Growth Rate | 6.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.38 | |||||
| 9-Day RSI | 68.02 | |||||
| 14-Day RSI | 63.33 | |||||
| 6-1 Month Momentum % | 51.58 | |||||
| 12-1 Month Momentum % | 157.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.57 | |||||
| Quick Ratio | 4.57 | |||||
| Cash Ratio | 4.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 | |||||
| Shareholder Yield % | -0.56 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -101.7 | |||||
| ROA % | -76.18 | |||||
| ROIC % | -833.62 | |||||
| ROC (Joel Greenblatt) % | -2416.35 | |||||
| ROCE % | -106.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.1 | |||||
| Price-to-Tangible-Book | 2.09 | |||||
| EV-to-EBIT | -0.99 | |||||
| EV-to-EBITDA | -0.99 | |||||
| EV-to-FCF | -0.65 | |||||
| Price-to-Net-Current-Asset-Value | 2.25 | |||||
| Price-to-Net-Cash | 2.33 | |||||
| Earnings Yield (Greenblatt) % | -101.01 | |||||
| FCF Yield % | -68.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CMMB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chemomab Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.96 | ||
| Beta | 0.2 | ||
| Volatility % | 99.24 | ||
| 14-Day RSI | 63.33 | ||
| 14-Day ATR ($) | 0.148669 | ||
| 20-Day SMA ($) | 1.6095 | ||
| 12-1 Month Momentum % | 157.28 | ||
| 52-Week Range ($) | 0.42 - 2.55 | ||
| Shares Outstanding (Mil) | 18.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chemomab Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chemomab Therapeutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chemomab Therapeutics Ltd Frequently Asked Questions
What is Chemomab Therapeutics Ltd(CMMB)'s stock price today?
The current price of CMMB is $1.82. The 52 week high of CMMB is $2.55 and 52 week low is $0.42.
When is next earnings date of Chemomab Therapeutics Ltd(CMMB)?
The next earnings date of Chemomab Therapeutics Ltd(CMMB) is 2025-03-07 Est..
Does Chemomab Therapeutics Ltd(CMMB) pay dividends? If so, how much?
Chemomab Therapeutics Ltd(CMMB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers